LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely H3K4me1/2 and H3K9me1/2, using FAD as the cofactor. It is ubiquitously overexpressed in many types of cancers (breast, gastric, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Noce, Beatrice, Di Bello, Elisabetta, Fioravanti, Rossella, Mai, Antonello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932783/
https://www.ncbi.nlm.nih.gov/pubmed/36817147
http://dx.doi.org/10.3389/fphar.2023.1120911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932783/
https://www.ncbi.nlm.nih.gov/pubmed/36817147
http://dx.doi.org/10.3389/fphar.2023.1120911

Ejemplares similares